N. Moore

发表

R-CHOP with or without bevacizumab in patients with previously untreated diffuse large B-cell lymphoma: final MAIN study outcomes

L. Sehn, B. Coiffier, M. Pfreundschuh, 2014, Haematologica.

AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer.

R. Greil, F. André, V. Semiglazov, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy and Safety of Bevacizumab-Based Therapy in Elderly Patients with Advanced or Recurrent Nonsquamous Non-small Cell Lung Cancer in the Phase III BO17704 Study (AVAiL)

R. Ramlau, P. Zatloukal, N. Leighl, 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A randomized, controlled, double-blind phase III study (AVOREN) of bevacizumab/interferon-α2a vs placebo/interferon- α2a as first-line therapy in metastatic renal cell carcinoma

A. Ravaud, B. Melichar, C. Szczylik, 2007 .

Correlation of molecular subtypes with survival in AVAglio (bevacizumab [Bv] and radiotherapy [RT] and temozolomide [T] for newly diagnosed glioblastoma [GB]).

R. Bourgon, P. Hegde, W. Mason, 2014 .

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

Bohuslav Melichar, A. Ravaud, B. Melichar, 2007, The Lancet.

Comprehensive reassessment of plasma VEGFA (pVEGFA) as a candidate predictive biomarker for bevacizumab (Bv) in 13 pivotal trials (seven indications).

P. Hegde, L. Amler, C. Rabe, 2014 .

Efficacy and safety of first-line bevacizumab (BEV) plus interferon-{alpha}2a (IFN) in patients (pts) >=65 years with metastatic renal cell carcinoma (mRCC)

A. Ravaud, C. Szczylik, P. Pisa, 2008 .

4518 POSTER First-line bevacizumab improves progression-free survival with lower doses of interferon-a2a in the treatment of patients with metastatic renal cell carcinoma (AVOREN)

A. Ravaud, B. Melichar, C. Szczylik, 2007 .

4008 POSTER Bevacizumab/interferon-alpha2a provides a progression-free survival benefit in all prespecified patient subgroups as first-line treatment of metastatic renal cell carcinoma (AVOREN)

A. Ravaud, B. Melichar, C. Szczylik, 2007 .

S4-8: First results of AVEREL, a randomized phase III trial to evaluate bevacizumab (BEV) in combination with trastuzumab (H) + docetaxel (DOC) as first-line therapy for HER2−positive locally recurrent/metastatic breast cancer (LR/mBC)

R. Greil, F. André, V. Semiglazov, 2011 .

Patients With Proneural Glioblastoma May Derive Overall Survival Benefit From the Addition of Bevacizumab to First-Line Radiotherapy and Temozolomide: Retrospective Analysis of the AVAglio Trial.

R. Bourgon, P. Hegde, W. Mason, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy of bevacizumab with cisplatin and gemcitabine in Asian patients with advanced or recurrent non‐squamous non‐small cell lung cancer who have not received prior chemotherapy: A substudy of the Avastin in Lung trial

S. Thongprasert, Chun-Ming Tsai, T. Hsia, 2011, Asia-Pacific journal of clinical oncology.

Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)

R. Ramlau, J. von Pawel, P. Zatloukal, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil.

R. Ramlau, J. von Pawel, P. Zatloukal, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

6503 ORAL Efficacy and safety results from BO17704, a randomised, placebo-controlled phase III study of bevacizumab in combination with cisplatin and gemcitabine in patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC)

R. Ramlau, P. Zatloukal, N. Leighl, 2007 .

AVAglio: Phase 3 trial of bevacizumab plus temozolomide and radiotherapy in newly diagnosed glioblastoma multiforme

T. Cloughesy, O. Chinot, Z. Modrušan, 2011, Advances in therapy.

AVAglio: A phase III trial of bevacizumab added to standard radiotherapy and temozolomide in patients with newly diagnosed glioblastoma.

W. Mason, T. Cloughesy, R. Henriksson, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

6509 ORAL Management of hypertension (HTN) in patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC) receiving first-line cisplatin and gemcitabine with bevacizumab or placebo – results from randomised phase III trial BO17704

R. Ramlau, P. Zatloukal, N. Leighl, 2007 .

Bleeding events in bevacizumab-treated cancer patients who received full-dose anticoagulation and remained on study

H. Hurwitz, J. Yi, N. Moore, 2011, British Journal of Cancer.

Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil.

R. Ramlau, J. von Pawel, P. Zatloukal, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Patients With Proneural Glioblastoma May Derive Overall Survival Benefit From the Addition of Bevacizumab to First-Line Radiotherapy and Temozolomide: Retrospective Analysis of the AVAglio Trial.

R. Bourgon, P. Hegde, W. Mason, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.